EGFR Mutations in Lung Cancer: Types, Testing, and Treatment Implications
Clinical Significance
EGFR (epidermal growth factor receptor) mutations are the most common actionable driver in non-small cell lung cancer (NSCLC), especially adenocarcinoma. Prevalence: ~15% Western, 35–50% Asian; higher in never-smokers, women. Predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs).
Major Mutation Classes
| Class | Examples | Frequency | TKI Sensitivity |
|---|---|---|---|
| Classical (sensitizing) | Exon 19 deletion (del19), L858R (exon 21) | ~85–90% of EGFR+ | High (1st/2nd/3rd gen) |
| Exon 20 insertions | A767_V769dup, D770_N771insSVD, etc. | ~4–10% | Resistant to 1st/2nd/3rd gen; sensitive to exon 20-specific (amivantamab, mobocertinib, CLN-081) |
| Resistance (acquired) | T790M (exon 20), C797S, L718Q, G724S, etc. | Post-TKI progression | T790M → osimertinib (3rd gen); C797S cis/trans → combo strategies |
| Uncommon sensitizing | G719X (exon 18), L861Q (exon 21), S768I (exon 20) | ~5–10% | Variable; often respond to afatinib/osimertinib |
Testing Standards
- Method: NGS panel (tissue or liquid biopsy/ctDNA) – detects all classes + co-mutations (TP53, MET amp, PIK3CA).
- Timing: At diagnosis (advanced NSCLC adenocarcinoma); at progression on TKI (resistance mechanism).
- Liquid biopsy: Non-invasive; detects resistance earlier; tissue if negative/insufficient.
Treatment Algorithm (2024)
- 1st line (classical): Osimertinib (preferred; FLAURA OS benefit, CNS activity). Alternatives: afatinib, dacomitinib, gefitinib, erlotinib.
- 1st line (exon 20 ins): Amivantamab + chemo (PAPILLON) or mobocertinib (accelerated approval withdrawn US; available elsewhere).
- Progression on 1st/2nd gen: Test for T790M → osimertinib if +; else chemo ± bevacizumab.
- Progression on osimertinib: Biopsy/ctDNA for resistance mechanism → clinical trial (4th gen TKIs, combos) or chemo ± anti-angiogenic.
- Brain mets: Osimertinib penetrates BBB; local therapy (SRS) for symptomatic/oligoprogressive.
Key Co-Mutations Impacting Outcome
- TP53 co-mutation → shorter PFS, higher transformation risk.
- MET amplification → bypass resistance; capmatinib + osimertinib trials.
- RB1/PTEN loss → small cell transformation.
Emerging Horizons
- 4th-gen TKIs (BLU-945, BBT-207) targeting C797S.
- Antibody-drug conjugates (patritumab deruxtecan).
- Bispecifics (amivantamab).
- Neoadjuvant/adjuvant osimertinib (ADAURA – DFS benefit in stage IB–IIIA).
Bottom Line
EGFR testing is mandatory in non-squamous NSCLC. Mutation subclass determines first-line therapy. Serial monitoring (ctDNA) guides resistance management. Clinical trials offer next-line options.
Genetic Disorders - Related Articles
- Autosomal Genetic Disorders: Inheritance Patterns and Examples
- Understanding Elevated Liver Enzymes in Turner Syndrome
- ABO Blood Type Inheritance: Can Type A & Type B Parents Have a Type O Child?
- Lung Cancer & Genetics: Understanding Your Risk
- Understanding Chromosomal Abnormalities & Genetic Counseling
- Congenital Guillain-Barré Syndrome: Symptoms, Diagnosis & Urgent Care
- Understanding Dwarfism: Causes, Types, and Inheritance
